2020-2026年全球特用藥品合作條款及協議

利用基於 1,019 個真實案例的合約數據，了解專業製藥公司如何合作、達成交易並利用外部創新。

《2020-2026 年專業製藥合作條款與協議》提供了全球專業製藥領域 1,019 項合作交易的全面資訊。

專業製藥公司利用各種合作結構來確保獲得產品和技術，推進研發計劃，擴大商業性覆蓋範圍，並在關鍵治療領域建立產品組合。

本報告將這些活動匯總到一個資源中，使用戶能夠了解哪些公司正在合作、正在使用哪些交易結構、活動集中在哪些地區、正在披露哪些財務條款，以及專業製藥公司如何在開發和商業化的每個階段與外部合作夥伴合作。

本報告並未著重於具體的交易類型，而是對專業製藥領域的合作活動進行了廣泛的觀點，涵蓋了合作、授權、開發、商業化和其他合約形式。

本報告整合了全面的市場交易分析和金融基準、主要負責人資訊、詳細的交易記錄以及公開的合約文件。

本報告旨在為參與專業製藥合作的業務發展、許可、研究和評估、公司策略、投資組合策略、競爭情報分析和法律團隊提供參考。

了解專科製藥領域的合作趨勢

本報告分析了2020年至2026年專科藥物合作的發展趨勢，內容包括：

• 合作活動的年度趨勢
• 專業製藥領域最活躍的交易商
• 按交易類型分類的合作關係趨勢
• 按治療區域
• 技術類型
• 發展階段
• 根據已揭露的交易金額，主要交易金額
• 可用的財務條款
• 專業製藥公司合作策略的演變
• 本報告概述了整個市場活動的集中區域，以及各公司如何利用外部夥伴關係來建立和擴展其特藥產品組合。
• 比較各種專科製藥合作模式
• 專業製藥合作可以採取多種形式，具體取決於資產、研發階段、商業性機會以及相關各方的能力。

本報告探討了多種方法，其中包括以下幾種：

• 授權協議
• 研究與開發夥伴關係
• 聯合發展夥伴關係
• 商業化合約
• 銷售合約
• 製造和供應夥伴關係
• 期權和評估機制
• 其他多因素交易
• 這樣就可以比較不同的合作模式，而不是孤立地評估單一合約類型。
• 專科藥品交易財務條件基準

本報告詳細分析了專科藥物合作交易中揭露的財務條款，包括以下內容：

• 交易總額
• 預付款
• 里程碑付款
• 版稅率
• 用戶可以透過查看這些基準背後的具體交易，深入了解所揭露的經濟狀況的背景。
• 這為內部基準測試、機會評估、交易準備和談判提供了一個現實的基準。
• 財務基準只有在結合類似交易的結構、階段、權利和情況進行解讀時才最有用，而本報告提供了建立這種背景所必需的基礎交易資訊。
• 識別關鍵專業製藥領域的交易商和潛在的未來合作夥伴。
• 本報告列出了專業製藥領域最活躍的交易商，並提供了每家公司的交易歷史，以便用戶可以調查其過去的活動。

這有助於用戶識別以下內容：

• 公司積極尋求外部機會
• 有潛力的授權和合作夥伴
• 在特定治療領域反覆開展業務的組織
• 對特定技術表現出明顯興趣的公司
• 積極參與開發過程的交易商
• 競爭對手採取類似的投資組合策略
• 過往的交易記錄可以作為有用的證據，說明各家公司在哪些領域積極尋求外部創新。
• 了解專業製藥公司將業務重點放在哪些領域。

本報告從以下幾個面向分析合作關係趨勢：

• 交易類型
• 治療區域
• 技術類型
• 發展階段
• 公司
• 這樣一來，用戶就能了解哪些領域的合作活動日益增多，並專注於與特定產品、技術或策略目標最相關的交易。
• 了解專業製藥業的合約結構

根據交易詳情和資訊披露，用戶可以調查以下方面：

• 授予和保留的權利
• 許可範圍
• 負責研發工作
• 獨家版權
• 區域權利
• 智慧財產
• 發展和監管義務
• 製造和供應
• 商業化方面的責任
• 金錢補償
• 里程碑和版稅
• 管治
• 合約期限和終止條款
• 在考慮針對特種藥品的新型合作框架時，這些例子可以作為有用的參考。
• 從實際合約文件中學習
• 本報告提供了部分特種藥品交易的原始合約文件（如有公開版本）。

這些協議提供了僅憑新聞稿無法獲得的詳細信息，使用戶能夠檢驗每家公司如何記錄以下內容：

• 權利範圍
• 智慧財產
• 發展義務
• 獨家銷售權和銷售區域
• 財務狀況
• 里程碑觸發條件
• 特許權使用費規定
• 商業化方面的責任
• 製造和供應
• 合約終止及後續權利
• 對於準備或談判特殊藥物交易的團隊來說，獲取實際的合約措辭可以提供寶貴的見解，了解類似的合作關係在實踐中是如何建立的。
• 專業藥品交易的綜合名錄
• 本報告包含一個涵蓋 1,019 個專業製藥合作關係的綜合目錄，為識別相關的領先交易和公司資訊來源。

交易可依以下類別進行調查：

• 公司
• 發展階段
• 交易類型
• 治療區域
• 技術類型
• 交易金額
• 合約資訊揭露狀況
• 每筆交易都與其底層交易記錄相關聯，從而可以存取更多交易資訊和相關合約文件（如有）。
• 誰該使用這份報告？
• 業務拓展與授權團隊
• 識別類似的專科藥品交易、潛在合作夥伴及相關交易結構。
• 研究與評估團隊
• 我們確定哪些公司正在積極尋求相關治療領域和技術領域的產品、資產和技術。
• 專業製藥公司
• 我們對合作夥伴活動進行基準測試，以確定潛在合作夥伴，並了解我們的競爭對手如何利用外部創新來擴展其產品組合。
• 生技公司尋求與專業製藥公司建立合作關係
• 找出對相關資產、治療領域、技術和開發階段表現出明確興趣的公司。
• 企業策略與投資組合策略團隊
• 我們追蹤專業製藥公司如何建立其產品組合併利用外部機會。
• 競爭情報與市場情報團隊
• 我們按公司、治療領域、技術、開發階段和交易類型分析活動，以了解不斷變化的策略重點。
• 法律及交易團隊
• 我們將仔細審查公開的合約和以往的合約結構，以幫助您準備和談判交易。
• 我們將整個市場的專科藥品資訊轉化為針對特定公司的洞察。
• 符合資格的客戶將收到 Current Partnering 的報告，以及為高階主管量身訂製的合作關係簡報。
• 本簡報將說明有關專業製藥領域交易的基礎信息，並根據您的特定資產、技術、投資組合或合作目標量身定做。
• 如有需要，我們可以提供相關的類似交易、潛在的未來合作關係、競爭對手的活動、發展階段分析、交易結構、財務基準、忠誠度分析、合約見解以及其他專門為您特定情況選擇的資訊。
• 請索取樣本或聯絡 Current Partnering 討論本報告的內容以及我們是否可以為貴公司提供客製化分析。

目錄

執行摘要

第1章：引言

第2章：專業製藥業交易趨勢

• 多年來專業製藥領域合作關係的發展趨勢
• 專業製藥領域最活躍的交易實體
• 按交易類型分類的專業製藥合作關係
• 按治療領域分類的專科藥物合作關係
• 按技術類型分類的特藥合作
• 專業製藥領域合作的條款與條件
  • 特藥合作專案合約總價值
  • 特殊藥品交易中的預付款
  • 特殊藥品交易中的里程碑付款
  • 特種藥品的特許權使用費率

第3章：典型的專科藥品交易

• 按交易量排名的前幾大專科藥品交易

第4章：特種藥品交易中最活躍的交易商

• 最活躍的專業藥物交易商
• 最活躍的專業製藥夥伴簡介

第5章：專業藥品合約交易指南

• 專業藥品交易指南

第6章：依技術類型分類的特用藥品交易

附錄

• 附錄 1 - 依公司分類的特用藥品交易（A-Z）
• 附錄 2 - 依研發階段分類的特殊藥品交易
• 附錄 3 - 依交易類型分類的特用藥品交易
• 附錄 4 - 按治療領域分類的專科藥物交易
• 附錄5 - 交易類型的定義
• 附錄 6 - 參考文獻
• 關於生物製藥研究
• Current Partnering
• Current Agreements
• 理想合作夥伴近期報告標題

Specialty Pharmaceutical Partnering Terms and Agreements 2020-2026

Understand how specialty pharmaceutical companies partner, structure transactions and access external innovation using intelligence from 1,019 real-world agreements.

Specialty Pharmaceutical Partnering Terms and Agreements 2020-2026 provides comprehensive intelligence on 1,019 partnering deals across the global specialty pharmaceutical sector.

Specialty pharmaceutical companies use a wide range of partnership structures to access products and technologies, advance development programs, extend commercial reach and build portfolios in focused therapeutic markets.

The report brings this activity together in one resource, enabling users to understand who is partnering, which deal structures are being used, where activity is concentrated, what financial terms have been disclosed and how specialty pharma companies are working with external partners across development and commercialization.

Rather than focusing on a single transaction type, the report provides a broad view of specialty pharmaceutical partnering across collaboration, licensing, development, commercialization and other agreement structures.

It combines market-wide deal analysis with financial benchmarking, leading dealmaker intelligence, detailed transaction records and access to publicly available contract documents where available.

The report is designed for business development, licensing, search and evaluation, corporate strategy, portfolio strategy, competitive intelligence and legal teams involved in specialty pharmaceutical partnering.

Understand the specialty pharmaceutical partnering landscape

The report analyzes specialty pharmaceutical partnering from 2020 to 2026, including:

• Trends in partnering activity by year
• Most active specialty pharmaceutical dealmakers
• Partnering activity by deal type
• Therapy area
• Technology type
• Stage of development
• Leading deals by disclosed value
• Financial terms where available
• How specialty pharmaceutical partnering strategies are evolving
• This provides a market-wide view of where activity is concentrated and how companies are using external partnerships to build and expand specialty pharmaceutical portfolios.
• Compare different specialty pharma partnership models
• Specialty pharmaceutical partnerships can take many forms depending on the asset, development stage, commercial opportunity and capabilities of the parties.

The report enables users to investigate multiple approaches, including:

• Licensing agreements
• Research and development collaborations
• Co-development partnerships
• Commercialization agreements
• Distribution arrangements
• Manufacturing and supply partnerships
• Option and evaluation structures
• Other multi-component transactions
• This makes it possible to compare alternative partnering routes rather than evaluating individual agreement types in isolation.
• Benchmark specialty pharmaceutical deal financials

The report provides dedicated analysis of disclosed financial terms across specialty pharmaceutical partnering transactions, including:

• Headline deal values
• Upfront payments
• Milestone payments
• Royalty rates
• Users can investigate the individual transactions behind these benchmarks to understand the circumstances surrounding the disclosed economics.
• This provides real-world reference points for internal benchmarking, opportunity assessment, deal preparation and negotiation.
• Financial benchmarks are most useful when interpreted alongside the structure, stage, rights and circumstances of comparable transactions rather than as standalone averages, and the report provides the underlying deal intelligence needed to establish that context.
• Identify leading specialty pharmaceutical dealmakers and prospective partners
• The report identifies the most active specialty pharmaceutical dealmakers and provides company-level transaction histories that enable users to investigate their previous activity.

This can help users identify:

• Companies actively seeking external opportunities
• Prospective licensing and collaboration partners
• Organizations repeatedly active in particular therapy areas
• Companies with demonstrated interest in specific technologies
• Dealmakers active at relevant stages of development
• Competitors pursuing similar portfolio strategies
• Previous transaction activity provides useful evidence of where individual companies have demonstrated an appetite for external innovation.
• Understand where specialty pharma activity is concentrated

The report analyzes partnering by:

• Deal type
• Therapy area
• Technology type
• Stage of development
• Company
• This enables users to identify which areas are attracting partnering activity and to focus on the subset of transactions most relevant to a particular product, technology or strategic objective.
• Understand how specialty pharmaceutical agreements are structured

Depending on the transaction and available disclosure, users can investigate areas including:

• Rights granted and retained
• Licensing scope
• Research and development responsibilities
• Exclusivity
• Geographic rights
• Intellectual property
• Development and regulatory obligations
• Manufacturing and supply
• Commercialization responsibilities
• Financial consideration
• Milestones and royalties
• Governance
• Term and termination provisions
• These real-world examples provide useful reference points when considering how a new specialty pharmaceutical partnership might be structured.
• Learn from real-world contract documents
• Where publicly available, the report provides access to underlying contract documents for selected specialty pharmaceutical transactions.

These agreements can provide substantially more detail than press releases alone, enabling users to examine how companies have documented matters including:

• Scope of rights
• Intellectual property
• Development obligations
• Exclusivity and territory
• Financial terms
• Milestone triggers
• Royalty provisions
• Commercialization responsibilities
• Manufacturing and supply
• Termination and continuing rights
• For teams preparing or negotiating a specialty pharmaceutical transaction, access to real agreement language provides valuable insight into how comparable partnerships have been structured in practice.
• Comprehensive specialty pharmaceutical deal directory
• The report includes a comprehensive directory of 1,019 specialty pharmaceutical partnering deals, providing an extensive resource for identifying relevant precedent transactions and companies.

Deals can be investigated by:

• Company
• Stage of development
• Deal type
• Therapy area
• Technology type
• Deal value
• Contract availability
• Individual transactions are linked to their underlying deal records, providing a route to further deal information and associated contract documentation where available.
• Who should use this report?
• Business Development and Licensing teams
• Identify comparable specialty pharma transactions, prospective partners and relevant deal structures.
• Search and Evaluation teams
• Understand which companies are actively seeking products, assets and technologies across relevant therapy and technology areas.
• Specialty Pharmaceutical Companies
• Benchmark partnering activity, identify prospective partners and understand how peer companies are using external innovation to expand portfolios.
• Biotechnology Companies Seeking Specialty Pharma Partners
• Identify companies with demonstrated interest in relevant assets, therapeutic areas, technologies and development stages.
• Corporate and Portfolio Strategy teams
• Track how specialty pharmaceutical companies are building portfolios and accessing external opportunities.
• Competitive and Market Intelligence teams
• Analyze activity by company, therapy area, technology, stage and transaction type to understand evolving strategic priorities.
• Legal and Transaction teams
• Review publicly available contracts and precedent agreement structures to support transaction preparation and negotiation.
• Turn market-wide specialty pharma intelligence into company-specific insight
• For qualifying customers, Current Partnering can also provide a Customized Executive Partnering Briefing alongside the report.
• The briefing applies the underlying specialty pharmaceutical deal intelligence to the customer's own assets, technologies, portfolio or partnering objectives.
• Depending on requirements, this can include relevant comparable transactions, prospective partners, competitor activity, development-stage analysis, deal structures, financial benchmarks, royalty analysis, contract insights and other intelligence selected specifically for the client's situation.
• Request a sample or contact Current Partnering to discuss the report and whether a customized analysis can be provided for your organization.

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in specialty pharmaceutical dealmaking

• 2.1. Introduction
• 2.2. Specialty pharmaceutical partnering over the years
• 2.3. Most active specialty pharmaceutical dealmakers
• 2.4. Specialty pharmaceutical partnering by deal type
• 2.5. Specialty pharmaceutical partnering by therapy area
• 2.6. Specialty pharmaceutical partnering by technology type
• 2.7. Deal terms for specialty pharmaceutical partnering
  • 2.7.1 Specialty pharmaceutical partnering headline values
  • 2.7.2 Specialty pharmaceutical deal upfront payments
  • 2.7.3 Specialty pharmaceutical deal milestone payments
  • 2.7.4 Specialty pharmaceutical royalty rates

Chapter 3 - Leading specialty pharmaceutical deals

• 3.1. Introduction
• 3.2. Top specialty pharmaceutical deals by value

Chapter 4 - Most active specialty pharmaceutical dealmakers

• 4.1. Introduction
• 4.2. Most active specialty pharmaceutical dealmakers
• 4.3. Most active specialty pharmaceutical partnering company profiles

Chapter 5 - Specialty pharmaceutical contracts dealmaking directory

• 5.1. Introduction
• 5.2. Specialty pharmaceutical contracts dealmaking directory

Chapter 6 - Specialty pharmaceutical dealmaking by technology type

Appendices

• Appendix 1 - Specialty pharmaceutical deals by company A-Z
• Appendix 2 - Specialty pharmaceutical deals by stage of development
• Appendix 3 - Specialty pharmaceutical deals by deal type
• Appendix 4 - Specialty pharmaceutical deals by therapy area
• Appendix 5 - Deal type definitions
• Appendix 6 - Further reading
• About Biopharma Research
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Specialty pharmaceutical partnering since 2019
• Figure 2: Active specialty pharmaceutical dealmaking activity 2019-2024
• Figure 3: Specialty pharmaceutical partnering by deal type since 2019
• Figure 4: Specialty pharmaceutical partnering by disease type since 2019
• Figure 5: Specialty pharmaceutical partnering by technology type since 2019
• Figure 6: Specialty pharmaceutical deals with a headline value
• Figure 7: Specialty pharmaceutical deals with an upfront value
• Figure 8: Specialty pharmaceutical deals with a milestone value
• Figure 9: Specialty pharmaceutical deals with a royalty rate value
• Figure 10: Top specialty pharmaceutical deals by value since 2019
• Figure 11: Most active specialty pharmaceutical dealmakers 2019-2024